01

ABBVIE

U.S.A

Compamed

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-01-07

AVIBACTAM SODIUM; CEFTAZIDIME

US Patent Number : 7112592

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 206494

Patent Use Code : U-2508

Patent Use Description :

Patent Expiration Date : 2026-01-07

Product Web Link

Corporate PDF

02

ABBVIE

U.S.A

Compamed

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-01-07

AVIBACTAM SODIUM; CEFTAZIDIME

US Patent Number : 7112592

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 206494

Patent Use Code : U-2244

Patent Use Description :

Patent Expiration Date : 2026-01-07

Product Web Link

Corporate PDF

03

ABBVIE

U.S.A

Compamed

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-01-07

AVIBACTAM SODIUM; CEFTAZIDIME

US Patent Number : 7112592

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 206494

Patent Use Code : U-282

Patent Use Description : METHOD OF TREATING BAC...

Patent Expiration Date : 2026-01-07

Product Web Link

Corporate PDF

04

ABBVIE

U.S.A

Compamed

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-01-07

AVIBACTAM SODIUM; CEFTAZIDIME

US Patent Number : 7112592

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 206494

Patent Use Code : U-3818

Patent Use Description :

Patent Expiration Date : 2026-01-07

Product Web Link

Corporate PDF

05

ABBVIE

U.S.A

Compamed

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-06-15

AVIBACTAM SODIUM; CEFTAZIDIME

US Patent Number : 9284314

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 206494

Patent Use Code :

Patent Use Description :

Patent Expiration Date : 2032-06-15

Product Web Link

Corporate PDF

06

ABBVIE

U.S.A

Compamed

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-11-12

AVIBACTAM SODIUM; CEFTAZIDIME

US Patent Number : 7612087

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 206494

Patent Use Code :

Patent Use Description :

Patent Expiration Date : 2026-11-12

Product Web Link

Corporate PDF

07

ABBVIE

U.S.A

Compamed

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2031-08-12

AVIBACTAM SODIUM; CEFTAZIDIME

US Patent Number : 8471025

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 206494

Patent Use Code :

Patent Use Description :

Patent Expiration Date : 2031-08-12

Product Web Link

Corporate PDF

08

ABBVIE

U.S.A

Compamed

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-06-15

AVIBACTAM SODIUM; CEFTAZIDIME

US Patent Number : 8969566

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 206494

Patent Use Code :

Patent Use Description :

Patent Expiration Date : 2032-06-15

Product Web Link

Corporate PDF

09

ABBVIE

U.S.A

Compamed

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-10-08

AVIBACTAM SODIUM; CEFTAZIDIME

US Patent Number : 8835455

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 206494

Patent Use Code :

Patent Use Description :

Patent Expiration Date : 2030-10-08

Product Web Link

Corporate PDF

10

ABBVIE

U.S.A

Compamed

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-06-15

AVIBACTAM SODIUM; CEFTAZIDIME

US Patent Number : 9695122

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 206494

Patent Use Code :

Patent Use Description :

Patent Expiration Date : 2032-06-15

Product Web Link

Corporate PDF

AVYCAZ

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

39 API Suppliers

18 USDMF

16 CEP/COS

6 JDMF

4 EU WC

4 KDMF

4 NDC API

14 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

3 Drugs in Development

INTERMEDIATES

6 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

221 FDF Dossiers

42 FDA Orange Book

100 Europe

6 Canada

16 South Africa

57 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

POWDER;INTRAVENOUS - EQ 0.5GM BASE;2GM/VIAL

INJECTABLE;INJECTION - 1GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - 2GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - 500MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - 6GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 20MG BASE/ML

INJECTABLE;INJECTION - EQ 40MG BASE/ML

INJECTABLE;INJECTION - EQ 1GM BASE

INJECTABLE;INJECTION - EQ 2GM BASE

RELATED EXCIPIENT COMPANIES

1 Actylis

1 Kerry

1 Microlex e.U

1 Pluviaendo

1 Roquette

EXCIPIENTS BY APPLICATIONS

2 Parenteral

2 Fillers, Diluents & Binders

1 Co-Processed Excipients

1 Taste Masking

DIGITAL CONTENT

4 DATA COMPILATION #PharmaFlow

25 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions

82 Finished Drug Prices

8 Annual Reports

MARKET PLACE

20 APIs

20 FDF Dossiers

PATENTS & EXCLUSIVITIES

10 US Patents

4 US Exclusivities

16 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM

2 USP

4 Others

Filters

01

02

03

04

05

06

07

08

09

10

INJECTABLE;INJECTION - 1GM/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - 2GM/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - 500MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - 6GM/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons